Specialization
Radiation Oncologist
Focus of research
Implementation of new treatment options such as MRI guided radiotherapy for different groups of oncological patients such as renal cancer patients
Improving outcomes for patients with pancreatic cancer
Improving outcomes for patients with renal cell carcinoma
In addition to a special interest in Neuro-Oncology and intracranial radiosurgery, as a radiation oncologist, I have been a core member of the clinical team setting up MR-guided adaptive radiotherapy program at the Amsterdam University medical center since 2015 and have set up the clinical program for stereotactic MR-guided adaptive radiation therapy for prostate-, renal- and pancreatic cancer.
In collaboration with the Dutch Pancreatic Cancer Group, I am in (co-)charge of several multicenter pancreatic cancer studies such as:
The PANCOSAR study - a randomized study in which the value of SABR is studied in patients unfit for chemotherapy and with medically inoperable pancreatic cancer with localized disease.
The ARCADE study - a randomized study in which the added value of SABR to chemotherapy or BSC is studied in patients with an isolated local recurrence of primary resected pancreatic cancer.
The LAPSTAR study - a randomized study in which the added value of ablative SABR to chemotherapy is studied in patients with locally advanced pancreatic cancer.
After implementation gated MRI guided radiotherapy for patients with (recurrent) renal cell carcinoma, participation in and collaboration with the International Radiosurgery Oncology Consortium for Kidney (IROCK consortium) is essential to study the value of SABR as an ablative, non-invasive treatment option for this group of patients worldwide.